echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > End the hair loss nightmare Many new drugs are on the way.

    End the hair loss nightmare Many new drugs are on the way.

    • Last Update: 2020-09-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Hair loss does not appear to be a serious disease, but it has long been a global problem, with more than 40% of the total population in Western countries and about 250 million people in our country.
    the cause of hair loss, hair loss can be roughly divided into androgen hair loss, baldness and anti-cancer drug treatment caused by hair loss.
    the highest incidence of androgen hair loss (AGA), also known as male hair loss, mainly affecting the front, middle and top of the scalp.
    Baldness (AA), commonly known as "ghost shaving", is a sudden on-the-spot non-scarred inflammatory chronic relapse disorder characterized by limited circular hair loss, where approximately 5% to 10% of baldness develops progressively or rapidly develops into total or total baldness, where the hair of the entire scalp of the total bald patient is completely or almost completely shedded, while the whole body hair of the bald patient falls off.
    caused by anti-tumor drugs will mostly recover gradually after the chemotherapy session is over.
    treatment of baldness, domestic new drugs on the road hair loss derived from hair, hair implants, wigs and other industries in the domestic market is huge, about 10 billion yuan, but the real treatment of hair loss drug market there is still a big gap.
    different types of hair loss, there are naturally different treatment drugs due to the cause of morbidity.
    androgen hair loss (AGA) is caused by excessive androgens in the body under 5 alpha-reductase natural metabolites due to dehydrotestosterone (DHT).
    study showed that the incidence of AGA also increased with age, and the U.S. study found that 48 percent of the 266 healthy men between the ages of 18 and 49 had at least moderate AGA.
    , China's AGA drug market is expanding year by year and is expected to reach 4731 million by 2028, according to the prospecto.
    currently, DHT and androgen-insequentials (AR) are considered key mechanisms for AGA and are hot targets for therapeutic drug research in this field.
    's approved drugs for AGA are Minodor and non-anaesthetic, in which Minodor works by increasing blood supply to hair follicles, stimulating hair follicle cell growth, local anti-androgen action, and other multi-dimensional mechanisms, rather than amines that reduce DHT production by inhibiting the activity of 5 alpha-reductase.
    It is important to note, however, that non-anaeramines need to be taken continuously for more than 1 year to be effective and can be used in pregnant women to cause abnormalities and sexual side effects of male foetal genital development (e.g. libido loss, erectile dysfunction and ejaculation disorders).
    has started Phase II clinical, according to insight database, the domestic pioneer pharmaceutical industry Forrethan has also been developed for the treatment of AGA, is currently in phase II clinical stage.
    Foritan is an AR antagonist, and the results of the completed Phase I and Ib clinical trials show that the single and multiple doses of Forrethan are good for safety and tolerance for healthy Chinese subjects and do not exhibit adverse side effects.
    's pioneering pharmaceutical prospectus says the potential to attract more men with androgen hair loss than existing treatments is expected to change the market for androgen hair loss drugs.
    lack of treatment drugs for plaque baldness, several new drugs enter Phase III clinical baldness (AA) is the second most common type of hair loss worldwide, with approximately 147 million AA patients worldwide and approximately 4 million in China.
    half of these AA patients can heal themselves within a year, but patients who relapse after remission tend to progress to moderate to severe baldness, or even baldness, making treatment more difficult.
    has so far not been a universal treatment for baldness, and the FDA has not approved any drugs to treat AA.
    study found that the high expression of NKG2D protein in hair follicle cells in bald patients due to genetic or external stimulation, so that CD4, CD8 T cells, NK cells, etc. attack the hair follicles, hair follicle secretion of IL-15 through and JA K1 and JAK3 combine to activate T cells, which leads to an increase in IFN-cynxic secretion, which, when combined with IFN-gamma binders on hair follicle cells, activates more IL-15 secretions, forming a continuous stimulus circuit, and T-cells continue to proliferate.
    , JAK inhibitors have become one of the most popular drug candidates for the treatment of AA.
    according to insight database, some JAK inhibitors have been developed in China for the treatment of AA, such as Lilly's JAK1/2 inhibitor Barrettinib, Pfizer's JAK3 inhibitor PF-06651600, Zee-Pharma's Jacktini and Reshi Bio's SHR0302.
    , barrettinib and PF-06651600 are progressing faster and are currently in Phase III clinical phase, and both drugs were awarded breakthrough drug eligibility for AA treatment in the United States in September 2018 and April 2020, respectively.
    PF-06651600 is the first JAK inhibitor to enter clinical trials in China for the treatment of AA, with the following adaptations: for the treatment of patients with moderate to severe baldness (including total baldness (AT) and general baldness Pfizer is conducting two phase 2b/3 international multi-center clinical trials evaluating the efficacy and safety of PF-06651600 among AA subjects, according to the Drug Clinical Trials Registration and Information Disclosure Platform.
    Baricitinib, a JAK1/2 inhibitor developed by Lilly and Incyte, was approved by NMPA in June 2019 for the treatment of rheumatoid arthritis and is currently conducting Phase III studies to evaluate its safety and ability in patients with severe AA.
    Jacktini is a self-developed JAK kinase small molecule inhibitor with tablets and creams through its precision small molecule new drug research and development and industrialization platform of drug stabilization technology.
    currently, Zetam Bio is conducting Phase 2 clinical trials for the treatment of severe AA and medium- and high-risk bone marrow fibrosis, as well as two Phase 1 trials for graft resistance to host disease and idiopathic pulmonary fibrosis.
    addition, Zeppelin Bio is conducting phase I/II clinical trials for the treatment of mild moderate AA and mild moderate endexual dermatitis with Jacphetinie hydrochloric acid creams.
    SHR0302 is a SELF-developed JAK1 inhibitor that has been approved for clinical trials for ulcerative colitis, Crohn's disease, specific dermatitis, rheumatoid arthritis, strong scolitis and baldness.
    in addition, other JAK inhibitors abroad have been developed for the treatment of AA, such as Concert Pharmaceuticals' CTP-543, an oral JAK1/2 inhibitor, a ruxolitinib similar to ruxolitinib, which was granted fast-track and breakthrough drug eligibility by the FDA to treat AA.
    hope that the above-mentioned hair loss drugs can be approved as soon as possible, ending the nightmare of hair loss.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.